Longevity Peptides is a recurring topic in our peptide coverage. This hub collects every article tagged Longevity Peptides, newest first, each evidence-graded and tied to real, verifiable sources.
Epitalon, MOTS-c, humanin and FOXO4-DRI are marketed as telomere-lengthening, anti-aging peptides. We grade the real evidence — replicated cell-culture data, animal healthspan signals, and the total absence of a qualifying human anti-aging trial.
A clinical monograph on Vilon — the synthetic Lys-Glu dipeptide bioregulator marketed for immune and longevity support. Rodent and in-vitro signals only, no human RCT, and no legal compounding pathway in 2026.
A clinical monograph on Thymalin — the calf-thymus immune bioregulator from Khavinson's lab. Real human trial data graded B, a single-lineage evidence base, and a non-FDA-approved 2026 status.
A clinical monograph on SS-31 / elamipretide (Forzinity) — the cardiolipin-binding, mitochondria-targeted tetrapeptide. First FDA-approved for Barth syndrome in 2025, yet negative on every other large trial's primary endpoint.
A clinical monograph on the mitochondrial-derived peptide (MDP) axis — MOTS-c, humanin and the small humanin-like peptides (SHLP). One coherent mechanism, three very different maturity tiers, and zero approved human therapies.
A clinical monograph on humanin — the first mitochondrial-derived peptide. Deep preclinical cytoprotection data, intriguing human biomarker correlations, zero interventional human trials, and a real tumor-promotion caveat.
A clinical monograph on epithalamin — the bovine pineal-gland peptide extract that is the natural precursor of synthetic epitalon. A provocative single-program human mortality dataset, no independent RCT, and an unsettled 2026 legal status.
A clinical monograph on epitalon (epithalon, AEDG) — the synthetic pineal tetrapeptide marketed as a telomerase-activating geroprotector. Real circadian and cell-culture signals, no Western RCT, and a 2026 FDA inflection point.
Longevity Peptides is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged Longevity Peptides, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.